# Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

> **NCT01017133** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 56 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** fludeoxyglucose F 18
- **RADIATION:** Fluorine F 18 EF5
- **PROCEDURE:** Positron emission tomography

## Key facts

- **NCT ID:** NCT01017133
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2012-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017133, "Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01017133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*